Kornimate/medical-research-clean huggingface dataset:
mindfulness meditation for epilepsy

Conditions: Epilepsy

Summary: in one-third of epileptic patients treated in france, seizures persist despite drug treatment. these so-called "refractory" epilepsies are among the most severe. only a minority of patients with refractory epilepsy can undergo surgery. the other options available are based on brain or vagus nerve stimulation interventions which clinical effectiveness is still being studied. alternative therapies are needed both to decrease the frequency of patients' seizures and to improve their quality of life. the practice of mindfulness meditation has recently been included in the recommendations of the international league against epilepsy in order to alleviate anxiety or depression comorbid symptoms. this study falls within this framework by targeting two aspects of the pathology.

through the development of standardized protocols, mindfulness meditation has been introduced as a complementary treatment to prevent the relapse of depression, and to reduce stress and improve well-being in many chronic conditions. epilepsy, which results from the activity of hyperexcitable circuits, is also associated with a disorganization of the physiological brain networks. studies in cognitive neuroscience in healthy subjects suggest that meditation induces lasting changes in the physiological networks of attention and default mode and could potentially compensate for dysfunctions of these networks in epileptic patients.

Eligibility criteria:
inclusion criteria: * for patients : * patients over 16 years of age; * epilepsy refractory to drug treatment according to the consensus criteria of the international league against epilepsy ; * affiliated with a health insurance plan; * free, informed and written consent signed by the patient, and parents for patients under the age of 18. * for healthy subjects : * healthy subjects 16 years of age and older; * affiliated with a health insurance plan; * free, informed and written consent signed by the volunteer, or parents, for volunteers under the age of 18. exclusion criteria: * for patients : * alcohol addiction disorders (assessed by the mini-international neuropsychiatric interview (mini) scale) ; * patients with psychogenic crises; * treatment with antidepressants; * simultaneous participation in other research that may interfere with the protocol; * persons of legal age subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty. * for healthy subjects : * psychiatric pathology and/or alcohol addiction disorders (evaluated by the mini scale) ; * simultaneous participation in other research that may interfere with the protocol; * persons of legal age subject to legal protection (protection of justice, guardianship, trusteeship), persons deprived of liberty.

Keywords: mindfulness meditation
study of effectiveness of mexyn-a

Conditions: Pruritus

Summary: atomised methoxymethane-in-aqua (mexyn-a) a new topical self-chilled, non-steroidal, non-flammable, pressurised spray which embodies in one simultaneous application, most of the currently recognised and effective chemical, mechanical and thermal anti-pruritic therapies and hydrotherapy.

the primary clinical endpoint was to establish mexyn-a efficacy and safety in abolishing or reducing pruritus related to cutaneous diseases, insect bites and poison ivy, within few seconds of the application. the secondary endpoint was to measure the itch free period as a result of the new intervention.

Eligibility criteria:
inclusion criteria: * patients suffering from severe itching due to : atopic dermatitis, contact dermatitis, psoriasis, urticaria, xerosis, prickly heat, genital pruritus, chicken pox, aquagenic pruritus, lichen planus, poison ivey, insect bites. * past experience with the use of at least one conventional medication for pruritus or conventional medication for the same disorder patients suffered. exclusion criteria: * patients who have taken any anti-pruritic drug during the month prior to participation. * patients who have taken drugs for any reason for 2 days prior to participating in the study.

Keywords: pruritus, itching, mexyn-a, clearitch, magicool-plus
the intelligent prevention and control system and strategy for the whole disease cycle of diabetic nephropathy

Conditions: Diabetic Nephropathy; T2DM

Summary: diabetic nephropathy is one of the most severe microvascular complications of diabetes and a major cause of premature death and disability. it has become a leading cause of end-stage renal failure both in china and worldwide, consuming substantial medical resources. the establishment of a comprehensive regulatory system for the development and progression of diabetic nephropathy is a critical need for effective prevention and control. however, there is a lack of representative cohorts covering the entire disease cycle of diabetic nephropathy both domestically and internationally, creating technical bottlenecks in comprehensively describing its developmental patterns. this project aims to expand and integrate existing large-sample natural population cohorts and prospective follow-up cohorts covering the entire disease cycle of diabetes and diabetic nephropathy. it will construct a panoramic life database to identify risk factors, clinical phenotypes, and multimodal biomarkers at different disease stages. by integrating multi-organ interactions (e.g., kidney, eye), the project will establish novel imaging and functional assessment technologies for microvascular complications. utilizing artificial intelligence to process multimodal medical data, it will build and validate risk prediction models and evaluation systems for the entire disease cycle of diabetic nephropathy. the project will develop effective intelligent prevention and treatment strategies for diabetic nephropathy, promote the adoption of new technologies, and establish a medical quality control system to provide services for medical institutions. ultimately, it aims to improve and sustain medical quality, reducing the incidence of end-stage renal disease.


Eligibility criteria:
t2dm inclusion criteria: * age ≥18 years old, gender is not limited * diagnosed with type 2 diabetes * a history of type 2 diabetes for more than 5 years * negative proteinuria * creatinine is normal * good compliance, voluntarily sign informed consent exclusion criteria: * incomplete medical records * lack of fundus microvascular examination or new imaging technology examination results data * combined with autoimmune diseases and tumors type 2 diabetes patients undergoing renal biopsy inclusion criteria: * age ≥18 years old, gender is not limited * diagnosed with type 2 diabetes * kidney damage (microalbuminuria or dominant albuminuria or renal insufficiency) * have undergone renal puncture biopsy and have complete renal pathological diagnosis data * sign informed consent voluntarily exclusion criteria: * gestational diabetes mellitus, special type diabetes mellitus * patients with hereditary kidney disease * combined with autoimmune diseases * diabetic nephropathy the indicators in the comprehensive assessment model of the risk of renal progression could not be obtained * there were pregnancy plans in the study period
renal protection against contrast medium-induced nephropathy in high risk patients undergoing coronary angiography

Conditions: Renal Insufficiency; Contrast Medium-induced Renal Insufficiency

Summary: this study evaluates the efficacy of remote ischemic preconditioning on preventing contrast medium-induced nephropathy in a population of high risk patients undergoing coronary angiography. half of participants will receive a preconditioning procedure while the other half will receive a sham procedure.

contrast medium-induced nephropathy has a big impact on clinical outcomes in patients suffering from renal insufficiency who undergo percutaneous coronary interventions. remote ischemic preconditioning is proved to protect myocardium in patients undergoing percutaneous coronary angiography. we will evaluate the effect of remote preconditioning on renal protection.

Eligibility criteria:
inclusion criteria: 1. patient headed to coronary angiography 2. glomerular filtration rate : * ≤ 40ml/min/1,73m² (mdrd equation) * or ≤ 60ml/min/1,73m² (mdrd equation) with 1 additional risk factor : age \> 75 years, nyha ≥ iii/iv, diabetes mellitus 3. signed informed consent exclusion criteria: 1. preoperative assessment / dilated cardiomyopathy assessment 2. acute st-segment elevation myocardial infarction 3. cardiogenic shock requiring pressor amine or systolic blood pressure \<80mmhg 4. resuscitation after cardiac arrest 5. intra-aortic balloon pump 6. contraindication for the repeted use of an upper-arm pressure cuff 7. extra-renal epuration 8. no health insurance coverage 9. legal incapacity (patients under tutorship, curatorship or judicial protection) 10. patient enrolled in another interventional trial or being in a washout period 11. incapacity/impossibility to undergo 12-month follow-up 12. patient refusal
drug interaction study of famotidine and atazanavir with ritonavir in hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this clinical research study is to assess the effect of famotidine given twice daily on atazanavir administered with ritonavir in hiv-infected subjects.


Eligibility criteria:
inclusion criteria: * hiv-infected male and female subjects between the ages of 18 to 65 years old with a bmi 18 to 35 kg/m² * prior to enrollment subjects must be currently receiving atazanavir/ritonavir plus at least 2 nrtis, must have plasma hiv rna \ 200 cells/mm³
the prostate liquid study (plis)

Conditions: Prostate Cancer

Summary: a multi-site study to evaluate the potential use of the chec test of seminal fluid as an additional triage test in stratifying patients for further tests.

a biomarker is a molecular substance that is an indicator of a biological condition. cambridge oncometrix believe that a semen biomarker may be able to predict the presence of prostate cancer. this study will allow work to be carried out on semen samples donated by men who have been identified by their gps as having a risk of prostate cancer. normally, gps refer men with symptoms or a raised psa to hospital to have an mri scan and a biopsy. the plis research team at the hospital will contact potential patients, who have been referred by their gps, before they have an mri or a biopsy, ask them if they are willing to take part in the study, consent them and ask them to provide a semen sample. semen samples will be produced by the potential participants at home into a seminal fluid collection container, they will also have to complete a study questionnaire. both the sample and the questionnaire will be returned to the central laboratory in cambridge using the stamped addressed envelope provided. in addition to providing a semen sample and completing a questionnaire, each participant will have two blood tests to measure male hormones. participants then exit the trial and their usual care carries on from this point. the plis study will register 400 men and of those it is hoped that 300 of them will be able to provide semen.

Eligibility criteria:
inclusion criteria: 1. - men over 40 years old with suspected prostate cancer who have been referred to a secondary care 2. - men able to produce a semen sample 3. - men able to have a prostate mpmri 4. - men who have given their written informed consent exclusion criteria: 1. - previous history of prostate biopsy 2. - contraindication to mri 3. - previous history of prostate surgery 4. - treatment with 5-alpha-reductase inhibitors at time of registration or during the prior 6 months 5. - evidence of urinary tract infection or history of acute prostatitis within the last month 6. - androgen replacement therapy within the last 3 months 7. - any other medical condition precluding standard diagnostic workup and collection of semen samples.
neuromuscular electrical stimulation for jaw-closing dystonia

Conditions: Muscle Dystonia

Summary: 6 patients with jaw-closing dystonia will be treated with neuromuscular electrical stimulation over 8 weeks. the distance the mouth can be opened voluntarily and the oro-mandibular dystonia questionnaire (omdq-25) will be employed to determine whether there is any objective change in jaw opening or evidence of functional improvement.


Eligibility criteria:
inclusion criteria: * jaw-closing dystonia, which may be primary or secondary to a neurodegenerative disease or medications. * unable to voluntarily open jaw fully on examination. * evidence of functional impairment resulting from dystonia including inability to completely open the jaw during speaking or eating to such an extent that it interferes with these tasks. * patient interested in participating, and willing to attend multiple treatment sessions in the neurology clinic. exclusion criteria: * presence of a cardiac pacemaker, implanted defibrillator, or other implanted electronic device. * inability to provide consent (either by the patient, spouse, or an identified power of attorney). * age under 18 years. * pregnancy.
clinical trial to evaluate the efficacy and safety of co-administration of jw0108+c2407 in patients with dyslipidemia

Conditions: Dyslipidemia

Summary: a multi-center, randomized, double-blind, parallel, phase ⅲ clinical trial to evaluate the efficacy and safety of co-administration of jw0108+c2407 in patients with dyslipidemia

to evaluate the efficacy and safety of jw0108+c2407 in dyslipidemia patients

Eligibility criteria:
inclusion criteria: * age of 19 years old at the time of written informed consent * patients with dyslipidemia exclusion criteria: * secondary dyslipidemia * patient who does not meet the specified tg, ldl-c level
treatment of periodontitis in obese individuals

Conditions: Obese; Obesity, Morbid; Periodontitis

Summary: obesity and gum diseases are highly prevalent in all parts of the world. obesity can negatively influence severity and progression rates of gum diseases. presence of fat in the body determines a general systemic state of inflammation. on the other hand, when gum diseases are successfully treated systemic and local inflammation decrease. in addition reductions in glycemic blood levels are also observed after treatment. periodontitis is one type of gum disease that is associated with bone loss. it could be treated within 24 hours by using a protocol, which combines dental debridement and mouthwash. this treatment protocol, named "one-stage full-mouth disinfection" works well in individuals of normal weight. however, there is no information whether it is effective in obese individuals or not. also, it should be clarified if obesity influences response to periodontal treatment. this study hypothesized that obesity impair response to periodontal treatment. therefore, the effects of the protocol "one-stage full-mouth disinfection" will be evaluated in obese individuals and normal weight controls. this evaluation will be based on the monitoring of several clinical, microbiological and biochemical parameters throughout 9 months. participants will answer validated questionnaires to evaluate if treatment of gum disease would be able to improve individual's quality of life. study population will be composed of 90 to 100 obese individuals (males or females; \> 18 years of age; smokers or non smokers; \> 12 natural teeth). participants will be classified into 5 groups according to their body mass index in normal weight (n = 15 to 20); overweight (n = 15 to 20); obesity i (n = 15 to 20); obesity ii (n = 15 to 20); obesity iii (n = 15 to 20). examinations will be performed before treatment and also 3, 6 and 9 months after treatment. this study will contribute to the knowledge on how obese individuals respond to this specific treatment protocol. also, having normal weight individuals as controls the present study will contribute to a better understanding about obesity, in its different severities, influence on periodontal treatment.


Eligibility criteria:
inclusion criteria: * moderate to advanced generalized chronic periodontitis * body mass index: \> 18.5 kg/m2 * minimum of 12 natural teeth * smokers, non-smokers or former-smokers exclusion criteria: * systemic diseases (diabetes, renal diseases, rheumatic diseases, osteoporosis and cardiovascular diseases) * pregnant and lactating women * hiv/ aids * periodontal treatment in the last year (before baseline appointment) * medication: immunosuppressive drugs, antibiotics in the past three months (before baseline appointment) ) * orthodontic appliance

Keywords: obesity periodontitis therapeutics chlorhexidine
dose-finding study of mci-196

Conditions: Chronic Kidney Disease; Dialysis; Hyperphosphatemia; Paediatric

Summary: the primary objective of this study is to determine the initial starting doses of colestilan (mci-196) in paediatric subjects with chronic kidney disease stage 5 on dialysis and with hyperphosphataemia.

this study has been terminated because of insufficient patient recruitment. there were no safety concerns.

Eligibility criteria:
inclusion criteria: * children aged 2 years to \<18 years with ckd stage 5 on dialysis (haemodialysis or peritoneal dialysis) for at least one month * the subject has a documented diagnosis of hyperphosphataemia, as demonstrated by serum phosphorus(p) levels above the age-related upper limit of normal kdoqi clinical practice guidelines for nutrition in children with ckd updated 2008) * the subject has been taking cbpb prior to enrolment into the study (i.e., prior to the screening visit) * the subject must have demonstrated serum p levels \>1.5 standard deviation (sd) above the kdoqi 2008 age-related mean value at any time during the wash-out period (this must be demonstrated after stopping treatment with cbpb) * at the time of randomisation, the subject must have demonstrated an increase in serum p levels from his/her most recent p central laboratory measurement by at least 10% above the pre-wash-out level exclusion criteria: * the subject has been diagnosed with hypocholesterolaemia (i.e., cholesterol levels below age-related normal ranges, per local practices) * the subject has current clinically significant medical comorbidities, which may substantially compromise subject safety, or expose him/her to undue risk, or interfere significantly with study procedures and which, in the opinion of the investigator, make the subject unsuitable for inclusion in the study (e.g., the subject currently has or has had a history of seizure disorders, dysphagia, swallowing disorders, predisposition to or current bowel obstruction, ileus or severe gastrointestinal \[gi\] disorders such as chronic or severe constipation \[as judged by the investigator\], intestinal stenosis, intestinal diverticulum, sigmoid colitis, gi ulcers, current or a history of gi bleeding, or major gi tract surgery) * the subject was treated with a combination of two or more phosphate binders within one month prior to screening * the subject cannot stop treatment (prescription or over-the counter) of any of the following orally taken medications during the wash-out period: any product containing calcium (ca), magnesium (mg), aluminium compounds, sevelamer, lanthanum, ketosteril * the subject is receiving immunosuppressant treatment for any medical condition at the time of randomisation or is expected to receive such treatment during the course of the study * the subject is considered unstable on his/her current treatment for ckd within one month prior to screening (e.g., subjects starting treatment with vitamin d or its analogues, or other agents/procedures that may influence bone mineral metabolism \[i.e., serum p and ca levels\])
study of biological determinants of bleeding postpartum

Conditions: Postpartum Hemorrhage

Summary: at the entry of the delivery room, a standard blood analysis will be performed (blood count, pt, aptt, fibrinogen, and d-dimer) for each women (if they are agree), according to the center's practices. the percentage of the immature platelets is a an additional parameter on the hemogram. the clinical assessments (recorded in medical records) and biological values will be used to determine if there is a correlation between these data and the occurrence of postpartum hemorrhage.


Eligibility criteria:
inclusion criteria: * woman giving birth in a maternity of finistère exclusion criteria: * refuse to participate in the study

Keywords: postpartum hemorrhage immature platelet
safety study of human igm (morab-028) to treat metastatic melanoma

Conditions: Melanoma

Summary: this research is being done to find out the safety of morab-028 in subjects with metastatic melanoma.


Eligibility criteria:
inclusion criteria: * histologically confirmed ajcc stage iiib, iiic or iv melanoma with injectable metastases (in transit, intradermal, or subcutaneous nodules) * tumor accessible to intra-tumoral injections * cumulative tumor volume great enough to accept morab-028 injections for a given dose level, based on intent to inject at a concentration of 1 mg/cm3 exclusion criteria: * are candidates for curative surgical excision or lymphadenectomy * prior non-surgical treatment within 4 weeks * known central nervous system (cns) tumor involvement or metastases * hypersensitivity to morab-028

Keywords: melanoma
efficiency of canine retraction using different reactivation intervals

Conditions: Class II Division 1 Malocclusion; Class III Malocclusion; Bimaxillary Protrusion; Crowding, Tooth

Summary: canine retraction after 1st premolar extracion into the extraction space is a routine treatment in orthodontics. orthodontic patients requiring first premolar extraction, canine retraction and maximum anchorage were recruited for this randomized controlled trial. a search of the literature did not indicate the ideal frequency of elastomeric chain reactivation for optimum canine retraction. the study was approved by the ethical committee. the first premolars were extracted. elastomeric chains were used to retract the canine distally into the 1st premolar space. the optimum reactivation interval was evaluated regarding the efficiency of treatment in terms of rate of canine retraction, canine tipping and rotation, root resorption and pain at the intervals of 2, 4, 6 and 8 weeks. three dimensional imaging, as well as digital scanning were the methods for data collection.

the canines, 2nd premolars, 1st molars and 2nd molars were bonded and banded. leveling and alignment was achieved. after the first premolar extraction, temporary anchorage devices were inserted interradicular between 2nd premolar and 1st molar. canine retraction was performed on a 0.016" x 0.022" stainless steel arch wire. a power arm was extended to apply the force closer to the center of resistance and achieve bodily movement. elastomeric chains were calibrated to deliver a force of 150g and extended from the power arm to the mini screws directly. recruited patients were randomly allocated to four groups according to the duration between the elastomeric chain reactivation. canine reactivation intervals were 2, 4, 6, or 8 weeks. cone beam computed tomography was performed before canine retraction and after 6 months of retraction. digital dental casts were taken before canine retraction and monthly for 6 months.

Eligibility criteria:
inclusion criteria: * patients requiring 1st premolar extraction (e.g bimaxillary dentoalveolar protrusion) * erupted full set of permanent teeth (excluding 3rd molars) exclusion criteria: * systemic diseases that would interfere with bone metabolism * craniofacial syndromes * congenitally missing or extracted permanent teeth. * periodontally compromised patients * smokers * pregnant women * previous orthodontic treatment